{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/CTNM/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-18T16:00:09.455Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":10261,"canonical_name":"Contineum Therapeutics, Inc.","cik":"0001855175","uei":null,"lei":null,"duns":null,"ticker":"CTNM"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":46},"count":46,"timeline":[{"ts":"2026-10-01","kind":"sec.filing","form_type":"144","title":"144 — Contineum Therapeutics, Inc. — 2026-10-01","url_slug":"/sec/cik-0001855175/144/0001950047-26-009932","accession_number":"0001950047-26-009932","importance":30},{"ts":"2026-09-14","kind":"sec.filing","form_type":"8-K","title":"8-K — Contineum Therapeutics, Inc. — 2026-09-14","url_slug":"/sec/cik-0001855175/8-k/0001628280-26-061834","accession_number":"0001628280-26-061834","importance":35},{"ts":"2026-09-08","kind":"sec.filing","form_type":"144","title":"144 — Contineum Therapeutics, Inc. — 2026-09-08","url_slug":"/sec/cik-0001855175/144/0001950047-26-009206","accession_number":"0001950047-26-009206","importance":30},{"ts":"2026-09-08","kind":"sec.filing","form_type":"4","title":"4 — Contineum Therapeutics, Inc. — 2026-09-08","url_slug":"/sec/cik-0001855175/4/0001628280-26-060962","accession_number":"0001628280-26-060962","importance":30},{"ts":"2026-09-01","kind":"sec.filing","form_type":"144","title":"144 — Contineum Therapeutics, Inc. — 2026-09-01","url_slug":"/sec/cik-0001855175/144/0001950047-26-008923","accession_number":"0001950047-26-008923","importance":30},{"ts":"2026-08-03","kind":"sec.insider.s","reporter":"Stengone Carmine N.","title":"CEO and President","shares":2500,"price_per_share":16.0116,"usd_value":40029,"security_title":"Class A Common Stock","importance":35.040029},{"ts":"2026-08-03","kind":"sec.filing","form_type":"144","title":"144 — Contineum Therapeutics, Inc. — 2026-08-03","url_slug":"/sec/cik-0001855175/144/0001950047-26-007509","accession_number":"0001950047-26-007509","importance":30},{"ts":"2026-08-03","kind":"sec.filing","form_type":"144","title":"144 — Contineum Therapeutics, Inc. — 2026-08-03","url_slug":"/sec/cik-0001855175/144/0001950047-26-007517","accession_number":"0001950047-26-007517","importance":30},{"ts":"2026-08-03","kind":"sec.filing","form_type":"4","title":"4 — Contineum Therapeutics, Inc. — 2026-08-03","url_slug":"/sec/cik-0001855175/4/0001628280-26-052031","accession_number":"0001628280-26-052031","importance":30},{"ts":"2026-08-03","kind":"sec.insider.m","reporter":"Stengone Carmine N.","title":"CEO and President","shares":2500,"price_per_share":1.01,"usd_value":2525,"security_title":"Class A Common Stock","importance":15.002525},{"ts":"2026-07-30","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Contineum Therapeutics, Inc. — 2026-07-30","url_slug":"/sec/cik-0001855175/10-q/0001628280-26-051054","accession_number":"0001628280-26-051054","importance":45},{"ts":"2026-07-30","kind":"sec.filing","form_type":"8-K","title":"8-K — Contineum Therapeutics, Inc. — 2026-07-30","url_slug":"/sec/cik-0001855175/8-k/0001628280-26-051051","accession_number":"0001628280-26-051051","importance":35},{"ts":"2026-07-27","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Contineum Therapeutics, Inc. — 2026-07-27","url_slug":"/sec/cik-0001855175/schedule-13g/0002012383-26-002243","accession_number":"0002012383-26-002243","importance":55},{"ts":"2026-07-13","kind":"sec.filing","form_type":"8-K","title":"8-K — Contineum Therapeutics, Inc. — 2026-07-13","url_slug":"/sec/cik-0001855175/8-k/0001628280-26-048023","accession_number":"0001628280-26-048023","importance":35},{"ts":"2026-07-10","kind":"sec.filing","form_type":"4","title":"4 — Contineum Therapeutics, Inc. — 2026-07-10","url_slug":"/sec/cik-0001855175/4/0001628280-26-047909","accession_number":"0001628280-26-047909","importance":30},{"ts":"2026-07-09","kind":"sec.insider.s","reporter":"Lorrain Daniel S.","title":"Chief Scientific Officer","shares":25,"price_per_share":16,"usd_value":400,"security_title":"Class A Common Stock","importance":35.0004},{"ts":"2026-07-09","kind":"sec.insider.m","reporter":"Lorrain Daniel S.","title":"Chief Scientific Officer","shares":25,"price_per_share":1.01,"usd_value":25,"security_title":"Class A Common Stock","importance":15.00002525},{"ts":"2026-07-08","kind":"sec.form144","reporter":"CARMINE STENGONE","title":"Director, Officer","shares":2500,"usd_value":36400,"security_title":"Common","approx_sale_date":"2026-07-08","accession_number":"0001950047-26-006968","importance":40.00728},{"ts":"2026-07-08","kind":"sec.insider.s","reporter":"Stengone Carmine N.","title":"CEO and President","shares":2500,"price_per_share":16,"usd_value":40000,"security_title":"Class A Common Stock","importance":35.04},{"ts":"2026-07-08","kind":"sec.insider.s","reporter":"Lorrain Daniel S.","title":"Chief Scientific Officer","shares":1015,"price_per_share":16,"usd_value":16240,"security_title":"Class A Common Stock","importance":35.01624},{"ts":"2026-07-08","kind":"sec.filing","form_type":"144","title":"144 — Contineum Therapeutics, Inc. — 2026-07-08","url_slug":"/sec/cik-0001855175/144/0001950047-26-006968","accession_number":"0001950047-26-006968","importance":30},{"ts":"2026-07-08","kind":"sec.filing","form_type":"4","title":"4 — Contineum Therapeutics, Inc. — 2026-07-08","url_slug":"/sec/cik-0001855175/4/0001628280-26-047710","accession_number":"0001628280-26-047710","importance":30},{"ts":"2026-07-08","kind":"sec.insider.m","reporter":"Stengone Carmine N.","title":"CEO and President","shares":2500,"price_per_share":1.01,"usd_value":2525,"security_title":"Class A Common Stock","importance":15.002525},{"ts":"2026-07-08","kind":"sec.insider.m","reporter":"Lorrain Daniel S.","title":"Chief Scientific Officer","shares":1015,"price_per_share":1.01,"usd_value":1025,"security_title":"Class A Common Stock","importance":15.00102515},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Contineum Therapeutics, Inc. — 2026-07-02","url_slug":"/sec/cik-0001855175/4/0001628280-26-047058","accession_number":"0001628280-26-047058","importance":30},{"ts":"2026-07-01","kind":"sec.form144","reporter":"Daniel Lorrain","title":"Officer","shares":9520,"usd_value":156033,"security_title":"Common","approx_sale_date":"2026-07-01","accession_number":"0001950047-26-006723","importance":40.03120656},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Lorrain Daniel S.","title":"Chief Scientific Officer","shares":5852,"price_per_share":15.6667,"usd_value":91682,"security_title":"Class A Common Stock","importance":35.0916815284},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Lorrain Daniel S.","title":"Chief Scientific Officer","shares":2501,"price_per_share":16.2369,"usd_value":40608,"security_title":"Class A Common Stock","importance":35.0406084869},{"ts":"2026-07-01","kind":"sec.filing","form_type":"4","title":"4 — Contineum Therapeutics, Inc. — 2026-07-01","url_slug":"/sec/cik-0001855175/4/0001628280-26-046654","accession_number":"0001628280-26-046654","importance":30},{"ts":"2026-07-01","kind":"sec.insider.m","reporter":"Lorrain Daniel S.","title":"Chief Scientific Officer","shares":4183,"price_per_share":1.01,"usd_value":4225,"security_title":"Class A Common Stock","importance":15.00422483},{"ts":"2026-06-30","kind":"sec.form144","reporter":"Daniel Lorrain","title":"Officer","shares":28826,"usd_value":432390,"security_title":"Common","approx_sale_date":"2026-06-30","accession_number":"0001950047-26-006667","importance":40.086478},{"ts":"2026-06-30","kind":"sec.form144","reporter":"TIMOTHY WATKINS","title":"Officer","shares":10833,"usd_value":162495,"security_title":"Common","approx_sale_date":"2026-06-30","accession_number":"0001950047-26-006664","importance":40.032499},{"ts":"2026-06-30","kind":"sec.form144","reporter":"CARMINE STENGONE","title":"Director, Officer","shares":10000,"usd_value":150000,"security_title":"Common","approx_sale_date":"2026-06-30","accession_number":"0001950047-26-006666","importance":40.03},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Lorrain Daniel S.","title":"Chief Scientific Officer","shares":28826,"price_per_share":16.0372,"usd_value":462288,"security_title":"Class A Common Stock","importance":35.4622883272},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Watkins Tim","title":"CMO & Head of Development","shares":10833,"price_per_share":16.0242,"usd_value":173590,"security_title":"Class A Common Stock","importance":35.1735901586},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Stengone Carmine N.","title":"CEO and President","shares":10000,"price_per_share":16.008,"usd_value":160080,"security_title":"Class A Common Stock","importance":35.16008},{"ts":"2026-06-30","kind":"sec.filing","form_type":"144","title":"144 — Contineum Therapeutics, Inc. — 2026-06-30","url_slug":"/sec/cik-0001855175/144/0001950047-26-006664","accession_number":"0001950047-26-006664","importance":30},{"ts":"2026-06-30","kind":"sec.insider.m","reporter":"Watkins Tim","title":"CMO & Head of Development","shares":10833,"price_per_share":4.5,"usd_value":48749,"security_title":"Class A Common Stock","importance":15.0487485},{"ts":"2026-06-30","kind":"sec.insider.m","reporter":"Lorrain Daniel S.","title":"Chief Scientific Officer","shares":28826,"price_per_share":1.01,"usd_value":29114,"security_title":"Class A Common Stock","importance":15.02911426},{"ts":"2026-06-30","kind":"sec.insider.m","reporter":"Stengone Carmine N.","title":"CEO and President","shares":7500,"price_per_share":1.01,"usd_value":7575,"security_title":"Class A Common Stock","importance":15.007575},{"ts":"2026-06-30","kind":"sec.insider.m","reporter":"Stengone Carmine N.","title":"CEO and President","shares":2500,"price_per_share":1.26,"usd_value":3150,"security_title":"Class A Common Stock","importance":15.00315},{"ts":"2026-06-26","kind":"sec.filing","form_type":"8-K","title":"8-K — Contineum Therapeutics, Inc. — 2026-06-26","url_slug":"/sec/cik-0001855175/8-k/0001628280-26-045804","accession_number":"0001628280-26-045804","importance":35},{"ts":"2026-06-01","kind":"sec.form144","reporter":"DANIEL LORRAIN","title":"Officer","shares":4170,"usd_value":56253,"security_title":"Common","approx_sale_date":"2026-06-01","accession_number":"0001950047-26-005377","importance":40.01125066},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Lorrain Daniel S.","title":"Chief Scientific Officer","shares":4170,"price_per_share":13.1564,"usd_value":54862,"security_title":"Class A Common Stock","importance":35.054862188},{"ts":"2026-06-01","kind":"sec.filing","form_type":"144","title":"144 — Contineum Therapeutics, Inc. — 2026-06-01","url_slug":"/sec/cik-0001855175/144/0001950047-26-005377","accession_number":"0001950047-26-005377","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"4","title":"4 — Contineum Therapeutics, Inc. — 2026-06-01","url_slug":"/sec/cik-0001855175/4/0001628280-26-039641","accession_number":"0001628280-26-039641","importance":30}]}